The global irritable bowel syndrome with constipation (IBS-C) drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market include the rise in the geriatric population, increase in the prevalence of gastrointestinal diseases such as constipation, the surge in level of stress, and unhealthy diet. Moreover, some other factors that are expected to fuel the market growth include an increase in awareness programs regarding the treatment and management of IBS and a surge in inclination toward IBS products that enhance therapeutic outcomes. Furthermore, the untapped potential opportunity across developing economies presents lucrative opportunities for the growth of the market during the forecast period. 

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. Signs & symptoms include abdominal pain, bloating, gas, cramping, and constipation or diarrhea. There are three types of irritable bowel syndrome such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Treatment of irritable bowel syndrome consists of stress relief, change in diet, proper medicines, and counseling. Medications available for the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used for the treatment of irritable bowel syndrome, which includes dicyclomine, peppermint oil, and hyoscyamine. In addition, an increase in the prevalence of gastrointestinal diseases such as constipation and diarrhea due to changes in lifestyles, an increase in the geriatric population, a surge in uptake of drugs such as linaclotide and lubiprostone, and a rise in patient awareness toward the treatment of irritable bowel syndrome are some other factors that will propel the growth of the global IBS-C drug market during the forecast period.  

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Type 

o By Prescription Type

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Catalent Pharma Solutions, Inc., AstraZeneca plc, and Abbott Laboratories, among others.  

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global IBS-C Drug Market Report by Segment

By Drug Type

• Lubiprostone

• Linaclotide

• Stimulant Laxatives

• Osmotic Laxatives

• Others

By Prescription Type

• Prescription Drugs

• Over-the-Counter Drugs

Global IBS-C Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa